FUNDAMENTALS · Fundamentals · JP Healthcare

Nipro (8086) Fundamentals 2026 — P/E 19.2x, Revenue Analysis | SniperIQ

Nipro (8086) is a JP-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥259.4B, trading at ¥1590.50 on the JPX. This SniperIQ fundamentals page covers Nipro's valuation (P/E 19.2x, P/B 0.9x), profitability (net margin 2.0%), revenue (¥660.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap¥259.4B
P/E (TTM)19.2x
Net Margin2.0%
Revenue (FY25)¥660.5B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Nipro's market cap?

Nipro (8086) has a market capitalization of approximately ¥259.4B, trading at ¥1590.50 on the JPX. Market cap moves with the live share price.

What is Nipro's P/E ratio?

Nipro's trailing twelve-month P/E ratio is 19.2x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nipro?

Nipro runs a net profit margin of 2.0%, a gross margin of 31.5%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nipro generate?

Nipro reported revenue of ¥660.5B for fiscal year 2025, with net income of ¥13.5B and earnings per share (EPS) of 82.8. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nipro pay a dividend?

Nipro offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Nipro financially healthy?

Nipro carries a debt-to-equity ratio of 2.33x and a current ratio of 1.39x, with a market beta of -0.01. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nipro a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nipro (8086) the key facts are: market cap ¥259.4B, P/E 19.2x, revenue ¥660.5B, 52-week range 1327.5-1760.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Nipro's full fundamentals live

Get Nipro's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Toho Holdings (8129) fundamentals · Nakanishi (7716) fundamentals · HLB Pharmaceutical (047920) fundamentals · Value Added Technology (043150) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons